MET three-lens brief
Evidence-based stock research on MET. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 97% of its 52-week range — near the top of the band.
- Trading at 97% of its 52-week range — near the top of the band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 9.7pp over 30 days.
- Negative free cash flow last quarterly (-$17.43B).
- 8-K filing filed 2026-06-29.
MET closed at $91.61 (+0.50%) as of 2026-07-10. Market cap: $58.95B. P/E (trailing) 17.5. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 9.7pp over 30 days.. Concerns: trading at 97% of its 52-week range — near the top of the band.; negative free cash flow last quarterly (-$17.43B).. Last quarter: Revenue $19.68B, net income $1.14B, free cash flow -$17.43B.
Why three lenses on MET, not one.
A single reasoning model has blind spots it doesn’t know about. We examine METacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/MET" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath MET brief"></iframe>